Dallas P Veitch1,2, Michael W Weiner1,3,4,5,6, Paul S Aisen7, Laurel A Beckett8, Charles DeCarli9, Robert C Green10, Danielle Harvey8, Clifford R Jack11, William Jagust12, Susan M Landau12, John C Morris13, Ozioma Okonkwo14, Richard J Perrin13,15,16, Ronald C Petersen17, Monica Rivera-Mindt18, Andrew J Saykin19,20, Leslie M Shaw21, Arthur W Toga22, Duygu Tosun3, John Q Trojanowski21. 1. Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA. 2. Department of Veterans Affairs Medical Center, Northern California Institute for Research and Education (NCIRE), San Francisco, California, USA. 3. Department of Radiology, University of California, San Francisco, San Francisco, California, USA. 4. Department of Medicine, University of California, San Francisco, San Francisco, California, USA. 5. Department of Psychiatry, University of California, San Francisco, San Francisco, California, USA. 6. Department of Neurology, University of California, San Francisco, San Francisco, California, USA. 7. Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA. 8. Division of Biostatistics, Department of Public Health Sciences, University of California Davis, Davis, California, USA. 9. Department of Neurology and Center for Neuroscience, University of California Davis, Davis, California, USA. 10. Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Broad Institute, Ariadne Labs, and Harvard Medical School, Boston, Massachusetts, USA. 11. Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA. 12. Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, USA. 13. Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, Missouri, USA. 14. Wisconsin Alzheimer's Disease Research Center and Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. 15. Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA. 16. Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA. 17. Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. 18. Department of Psychology, Fordham University, New York, New York, USA. 19. Department of Radiology and Imaging Sciences and Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, Indiana, USA. 20. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA. 21. Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Research, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 22. Laboratory of Neuroimaging, USC Stevens Institute of Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Abstract
INTRODUCTION: The Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, and biofluid samples available to researchers, resulting in more than 3500 publications. This review covers studies from 2018 to 2020. METHODS: We identified 1442 publications using ADNI data by conventional search methods and selected impactful studies for inclusion. RESULTS: Disease progression studies supported pivotal roles for regional amyloid beta (Aβ) and tau deposition, and identified underlying genetic contributions to Alzheimer's disease (AD). Vascular disease, immune response, inflammation, resilience, and sex modulated disease course. Biologically coherent subgroups were identified at all clinical stages. Practical algorithms and methodological changes improved determination of Aβ status. Plasma Aβ, phosphorylated tau181, and neurofilament light were promising noninvasive biomarkers. Prognostic and diagnostic models were externally validated in ADNI but studies are limited by lack of ethnocultural cohort diversity. DISCUSSION: ADNI has had a profound impact in improving clinical trials for AD.
INTRODUCTION: The Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, and biofluid samples available to researchers, resulting in more than 3500 publications. This review covers studies from 2018 to 2020. METHODS: We identified 1442 publications using ADNI data by conventional search methods and selected impactful studies for inclusion. RESULTS: Disease progression studies supported pivotal roles for regional amyloid beta (Aβ) and tau deposition, and identified underlying genetic contributions to Alzheimer's disease (AD). Vascular disease, immune response, inflammation, resilience, and sex modulated disease course. Biologically coherent subgroups were identified at all clinical stages. Practical algorithms and methodological changes improved determination of Aβ status. Plasma Aβ, phosphorylated tau181, and neurofilament light were promising noninvasive biomarkers. Prognostic and diagnostic models were externally validated in ADNI but studies are limited by lack of ethnocultural cohort diversity. DISCUSSION: ADNI has had a profound impact in improving clinical trials for AD.
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Jennifer Salazar; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2016-12-05 Impact factor: 21.566
Authors: Tharick A Pascoal; Sulantha Mathotaarachchi; Min Su Kang; Sara Mohaddes; Monica Shin; Ah Yeon Park; Maxime J Parent; Andrea L Benedet; Mira Chamoun; Joseph Therriault; Heungsun Hwang; A Claudio Cuello; Bratislav Misic; Jean-Paul Soucy; John A D Aston; Serge Gauthier; Pedro Rosa-Neto Journal: Nat Commun Date: 2019-06-04 Impact factor: 14.919
Authors: Marc Suárez-Calvet; Estrella Morenas-Rodríguez; Gernot Kleinberger; Kai Schlepckow; Miguel Ángel Araque Caballero; Nicolai Franzmeier; Anja Capell; Katrin Fellerer; Brigitte Nuscher; Erden Eren; Johannes Levin; Yuetiva Deming; Laura Piccio; Celeste M Karch; Carlos Cruchaga; Leslie M Shaw; John Q Trojanowski; Michael Weiner; Michael Ewers; Christian Haass Journal: Mol Neurodegener Date: 2019-01-10 Impact factor: 14.195
Authors: Betty M Tijms; Lisa Vermunt; Marissa D Zwan; Argonde C van Harten; Wiesje M van der Flier; Charlotte E Teunissen; Philip Scheltens; Pieter Jelle Visser Journal: Ann Clin Transl Neurol Date: 2018-07-20 Impact factor: 4.511
Authors: Christoforos Hadjichrysanthou; Stephanie Evans; Sumali Bajaj; Loizos C Siakallis; Kevin McRae-McKee; Frank de Wolf; Roy M Anderson Journal: Alzheimers Res Ther Date: 2020-06-13 Impact factor: 6.982
Authors: Michael Ewers; Gloria Biechele; Marc Suárez-Calvet; Christian Sacher; Tanja Blume; Estrella Morenas-Rodriguez; Yuetiva Deming; Laura Piccio; Carlos Cruchaga; Gernot Kleinberger; Leslie Shaw; John Q Trojanowski; Jochen Herms; Martin Dichgans; Matthias Brendel; Christian Haass; Nicolai Franzmeier Journal: EMBO Mol Med Date: 2020-08-10 Impact factor: 12.137
Authors: Dallas P Veitch; Michael W Weiner; Paul S Aisen; Laurel A Beckett; Charles DeCarli; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Susan M Landau; John C Morris; Ozioma Okonkwo; Richard J Perrin; Ronald C Petersen; Monica Rivera-Mindt; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; Duygu Tosun; John Q Trojanowski Journal: Alzheimers Dement Date: 2021-09-28 Impact factor: 16.655
Authors: Lilian Calderón-Garcidueñas; Jacqueline Hernández-Luna; Partha S Mukherjee; Martin Styner; Diana A Chávez-Franco; Samuel C Luévano-Castro; Celia Nohemí Crespo-Cortés; Elijah W Stommel; Ricardo Torres-Jardón Journal: Toxics Date: 2022-03-25